User talk:Craigventersmonster

Sockpuppeting
Please note that sockpuppeting and meatpuppeting are both forbidden on wikipedia. I have reverted your contribution to the BHRT page. WLU (t) (c) Wikipedia's rules: simple/complex 15:58, 30 June 2010 (UTC)

WLU-Thanks for bringing this to my attention, however, I was allowed to change my user name because of a technical problem with my first user name, so no, this is not sockpuppeting or meatpupeting, although it might appear that way to you, it is not technically.regards fromCraigventersmonster (talk) 16:53, 30 June 2010 (UTC)


 * Here you say Since I am a completely new user... yet just above you say I was allowed to change my user name because of a technical problem with my first user name... So - are you a new user or are you not? TFOWR 21:21, 30 June 2010 (UTC)
 * The other name didn't last long, so "completely new" would seem to be accurate in this case. --SarekOfVulcan (talk) 21:22, 30 June 2010 (UTC)
 * Ah, got it, thanks. TFOWR 21:23, 30 June 2010 (UTC)
 * Specifically, http://en.wikipedia.org/w/index.php?title=User_talk:Thx1138robert&action=history. --SarekOfVulcan (talk) 21:25, 30 June 2010 (UTC)
 * Naturally we have to note that the name of the account was not changed to Craigventersmonster, but was changed to Thx1138robert and (I hope) one or two (if appropriate) of these accounts will be abandoned, redirected and tagged with User Alternate Acct Name WLU (t) (c) Wikipedia's rules: simple/complex 22:51, 30 June 2010 (UTC)

Bioidentical hormone replacement therapy -Request For Page Protection to be UNDONE
Point made and addressed at talk:BHRT WLU (t) (c) Wikipedia's rules: simple/complex 22:51, 30 June 2010 (UTC)}} A perfectly good edit on the Bioidentical Hormone Therapy Page was undone (within minutes) by User talk:WLU who then made the page protected under a smokescreen of "sockpuppet" which is false. I was instructed to open a new account under a new name because my initial user name thx11138robot had the word fragment "bot". So I did so.

The issue is that User talk:WLU maintains a choke hold on the content of this page and will not allow any edits of the extremely biased information there. This is not what was intended by WIkipedia whose rules state that edits should be neutral.

The very first paragraph on the page state that the word bioidentical is ill-defined. This is incorrect and represents a biased viewpoint. Here is the edited text which was undone:

Definition of the Word Bioidentical

Firstly, the word, Bioidentical, is well-defined by the Miriam Webster Dictionary as "possessing identical molecular structure especially in relation to an endogenously produced substance ". Secondly, "bioidentical" is defined by Wiktionary as "identical to that which is naturally produced by the body." . The Endocrine Society Position Statement on Bioidentical Hormones definition is: “Bioidentical hormones” are defined as compounds that have exactly the same chemical and molecular structure as hormones that are produced in the human body. . This statement is also endorsed by the North Amerca Menopause Society. These sources are in agreement that the word, "bioidentical" has a well defined meaning.

Since I am a completely new user, I would ask any and all Wiki users and administrators to assist in having the page protection UNDONE, and allowing proper editing of the page. Craigventersmonster (talk) 21:19, 30 June 2010 (UTC)

Unprotection
You posted your request to have the page unprotected at WP:Requests for page protection, were turned down, and were told to discuss it on the article's talk page. Twice. Running around posting your content to assorted user pages and noticeboards is WP:Forum shopping, and could get you blocked. --SarekOfVulcan (talk) 21:29, 30 June 2010 (UTC)
 * Article's talk page, not my user page. --SarekOfVulcan (talk) 21:43, 30 June 2010 (UTC)

Identify Alternative Account
Usage:

fi:Malline:Altteri

For WLU- The alternate account is thx1138robert. Not sure I did this right, please advise...

Craigventersmonster (talk) 15:59, 1 July 2010 (UTC)

Review Articles Work Area
Moskowitz D http://www.ncbi.nlm.nih.gov/pubmed/17217322 Altern Med Rev. 2006 Sep;11(3):208-23. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks.Moskowitz D.

Abstract Numerous forms of estrogens and progestins are utilized for the treatment of menopausal complaints and associated conditions that occur temporally. Although known to be different with respect to molecular structure, receptor affinity, metabolism, and other physiological traits, most have been treated as if they were clinically identical. The majority of these hormone preparations, commonly referred to as hormone replacement therapy (HRT), should perhaps be more aptly referred to as hormone substitution therapy, as most of the therapies utilized do not exactly match those produced in the body. Research indicates these synthetic hormones vary clinically in safety and efficacy. As such, women and their physicians have, in increasing numbers, been opting for the use of bioidentical hormones; i.e., those that match the structure and function of hormones produced in the body. With greater utilization and research surrounding bioidentical hormones, the differences can now begin to be fully assessed and appreciated. This article reviews the disparities between synthetic and bioidentical estrogens and progestins/progesterone with respect to safety and efficacy; special attention is devoted to clinical outcomes in the breast, endometrium, bone, cardiovascular system, and brain. The studies reviewed suggest bioidentical progesterone does not have a negative effect on blood lipids or vasculature as do many synthetic progestins, and may carry less risk with respect to breast cancer incidence. '''Studies of both bioidentical estrogens and progesterone suggest a reduced risk of blood clots compared to non-bioidentical preparations. Bioidentical hormone preparations have demonstrated effectiveness in addressing menopausal symptoms. The author advocates for continued research on bioidentical hormones and concludes there is currently sufficient evidence to support their preferred use over that of their synthetic cousins'''. [PubMed - indexed for MEDLINE]Free Article Publication Types, MeSH Terms, SubstancesPublication Types: Review

Craigventersmonster (talk) 17:11, 1 July 2010 (UTC)

Campagnoli

http://www.ncbi.nlm.nih.gov/pubmed/15908197 J Steroid Biochem Mol Biol. 2005 Jul;96(2):95-108.

Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Unit of Endocrinological Gynecology, Sant'Anna Gynecological Hospital, Corso Spezia 60, 10126 Torino, Italy. ginendocrinol@oirmsantanna.piemonte.it

Abstract Controlled studies and most observational studies published over the last 5 years suggest that the addition of synthetic progestins to estrogen in hormone replacement therapy (HRT), particularly in continuous-combined regimen, increases the breast cancer (BC) risk compared to estrogen alone. By contrast, a recent study suggests that the addition of natural progesterone in cyclic regimens does not affect BC risk. This finding is consistent with in vivo data suggesting that progesterone does not have a detrimental effect on breast tissue. The increased BC risk found with the addition of synthetic progestins to estrogen could be due to the regimen and/or the kind of progestin used. Continuous-combined regimen inhibits the sloughing of mammary epithelium that occurs after progesterone withdrawal in a cyclic regimen. More importantly, the progestins used (medroxyprogesterone acetate and 19-Nortestosterone-derivatives) are endowed with some non-progesterone-like effects, which can potentiate the proliferative action of estrogens. Particularly relevant seem to be the metabolic and hepatocellular effects (decreased insulin sensitivity, increased levels and activity of insulin-like growth factor-I, and decreased levels of SHBG), which contrast the opposite effects induced by oral estrogen.

[PubMed - indexed for MEDLINE] Free PMC Article Publication Types, MeSH Terms, SubstancesPublication Types: Review

Craigventersmonster (talk) 17:26, 1 July 2010 (UTC)

Author's Conclusion: '''The balance of the in vivo evidence is that progesterone does not have a cancer-promoting effect on breast tissue. This provides a biological rationale for the finding that oral micronized progesterone added to estrogens in sequential or cyclic-combined regimens does not increase the risk of BC''' [26]. The greater BC risk persistently related to the use of HRT preparations containing estrogen and synthetic progestins seems in all likelihood due to the regimen and/or to the kind of progestin used. The “non-physiological” continuous-combined regimen, could increase the risk because it does not allow sloughing of lobular duct epithelium (such as occurs when progesterone declines at the end of the normal menstrual cycle). '''More importantly, many of the progestins used have several non-progesterone like actions that potentiate the proliferative effect of estrogens on breast tissue and estrogensensitive cancer cells. We therefore suggest that when HRT is indicated, preparations containing progesterone and not a synthetic progestin should be used,''' according to a sequential or cyclic-combined regimen. In this way the risk of endometrial cancer is minimized without increasing the risk of BC. Craigventersmonster (talk) 18:03, 1 July 2010 (UTC)

List of review articles from this page:

http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=17217322

1. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. Moskowitz D. Altern Med Rev. 2006 Sep;11(3):208-23. Review. [PubMed - indexed for MEDLINE]Free Article

2.The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Holtorf K. Postgrad Med. 2009 Jan;121(1):73-85. Review. [PubMed - indexed for MEDLINE]

3.Bioidentical hormone therapy: a review of the evidence. Cirigliano M. J Womens Health (Larchmt). 2007 Jun;16(5):600-31. Review. [PubMed - indexed for MEDLINE] Related citations

4.Bioidentical hormones for menopausal therapy. Sites CK. Womens Health (Lond Engl). 2008 Mar;4(2):163-71. Review. [PubMed - indexed for MEDLINE]

5.Unanswered questions in hormonal replacement therapy. Rebar RW. Exp Gerontol. 1994 May-Aug;29(3-4):447-61. Review. [PubMed - indexed for MEDLINE]

6.Bioidentical hormone therapy: a panacea that lacks supportive evidence. Boothby LA, Doering PL. Curr Opin Obstet Gynecol. 2008 Aug;20(4):400-7. [PubMed - indexed for MEDLINE]

7.Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. J Steroid Biochem Mol Biol. 2005 Jul;96(2):95-108. Review. [PubMed - indexed for MEDLINE]Free PMC ArticleFree text

8.Benefits and risks of hormone replacement therapy (HRT). Breckwoldt M, Keck C, Karck U. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):205-8. Review. [PubMed - indexed for MEDLINE]

9.Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies. Schairer C. Breast Cancer Res. 2002;4(6):244-8. Epub 2002 Oct 7. Review. [PubMed - indexed for MEDLINE]Free PMC ArticleFree text

10.Pregnancy, progesterone and progestins in relation to breast cancer risk. Campagnoli C, Abbà C, Ambroggio S, Peris C. J Steroid Biochem Mol Biol. 2005 Dec;97(5):441-50. Epub 2005 Oct 24. Review. [PubMed - indexed for MEDLINE]

11.Progestins in the menopause in healthy women and breast cancer patients. Pasqualini JR. Maturitas. 2009 Apr 20;62(4):343-8. Review. [PubMed - indexed for MEDLINE]

12.Bioidentical hormone therapy: a review. Boothby LA, Doering PL, Kipersztok S. Menopause. 2004 May-Jun;11(3):356-67. Review. [PubMed - indexed for MEDLINE]

13.[Hormone therapy of menopause and risk of breast cancer. Polemics and controversies] Sitruk-Ware R. Presse Med. 1994 Jan 8-15;23(1):38-42. Review. French. [PubMed - indexed for MEDLINE]

14.Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, Defreese DC, Gramling BA, Evans I, White E. Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1751-9. [PubMed - indexed for MEDLINE]Free PMC ArticleFree text

15.Hormone replacement therapy in menopausal women: Past problems and future possibilities. Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS. Gynecol Endocrinol. 2006 Oct;22(10):564-77. Review. [PubMed - indexed for MEDLINE]

16.Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. L'hermite M, Simoncini T, Fuller S, Genazzani AR. Maturitas. 2008 Jul-Aug;60(3-4):185-201. Epub 2008 Sep 5. Review. [PubMed - indexed for MEDLINE]

17.Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61. Epub 2007 Jul 24. [PubMed - indexed for MEDLINE]Free Article

18.Progestogen therapies: differences in clinical effects? Wiegratz I, Kuhl H. Trends Endocrinol Metab. 2004 Aug;15(6):277-85. Review. [PubMed - indexed for MEDLINE]

19.Bioidentical hormones for menopausal hormone therapy: variation on a theme. Fugh-Berman A, Bythrow J. J Gen Intern Med. 2007 Jul;22(7):1030-4. Epub 2007 Mar 7. [PubMed - indexed for MEDLINE]Free PMC ArticleFree text

20.Hormone replacement therapy and the risk of breast cancer. Cuzick J. Eur J Cancer. 2008 Nov;44(16):2344-9. Epub 2008 Sep 8. Review. [PubMed - indexed for MEDLINE]

Craigventersmonster (talk) 17:20, 1 July 2010 (UTC)